Transdermal Buprenorphine for Induction of Patients With Co-morbid Pain

Transdermal Buprenorphine for Induction of Patients With Co-morbid Pain is organized by California Society of Addiction Medicine (CSAM) and will be held from Mar 13, 2019 - Mar 16, 2022. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credit™.

Target Audience:
• Primary Care Physician who are beginning or planning to integrate buprenorphine for the treatment of opioid dependence into their practice.
• Associated health professionals who work in a setting that treats opioid dependent patients.
 
Description:
This webinar will review the complexities of carrying out buprenorphine inductions among patients with co-morbid pain, and a novel approach for managing these transitions.

Objectives:
• Describe new CDC guidelines for chronic pain management.
• Describe potential risks of precipitated withdrawal in patients on chronic opioids.
• Describe the risks and benefits of using transdermal buprenorphine in an induction for patients with co-morbid chronic pain and opioid use disorder.

Additional details will be posted as soon as they are available.